Open-Label Pilot Study of Modafinil for Methamphetamine Dependence
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Methamphetamine has become a major public health issue globally, particularly in the United States. Despite this, no effective pharmacotherapy for methamphetamine abuse has been developed to date. This 6-week, open-label pilot clinical trial examined the safety and tolerability of modafinil up to 400 mg/d in 8 methamphetamine-dependent individuals. Subjects were inducted onto modafinil at 400 mg/d for more than 3 days and remained on 400 mg/d for 4.5 weeks. Participants received weekly blister packs and underwent weekly individual cognitive behavioral therapy. Adjunctive contingency management procedures were used to enhance retention. Vital signs and supervised urine samples were obtained thrice weekly, and self-reported drug use and Hamilton anxiety and depression ratings were completed once weekly. Eight subjects (50% female, 100% white, aged 35-52 years) were enrolled. Four completed the 6-week study, 3 completed a portion, and 1 withdrew consent before completing intake. Results showed that systolic blood pressure (t = 1.09, P = 0.28), diastolic blood pressure, (t = 1.18, P = 0.24), and heart rate (t = 1.55, P = 0.13) did not change over time. Scores on the modafinil side effects checklist (t = -2.63, P = 0.01), Hamilton anxiety scale (t = -2.50, P = 0.018), and Hamilton depression scale (t = -3.25, P = 0.003) all decreased over time. The proportion of urine positive for amphetamines did not change over time (t = -0.52, P = 0.61), whereas self-reported methamphetamine use did (t = -2.86, P < 0.005). These results suggest that modafinil at 400 mg/d is safe and tolerable for methamphetamine-dependent individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
A double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159 · cited 1×
“Moreover, a doubleblind, placebo-controlled trial of modafinil (200 mg/d) supported the safety and tolerability of modafinil at this dose, and modafinil produced a trend toward a decrease in the number of methamphetamine-negative urines relative to placebo.(19) Meanwhile, an inpatient study examining the safety of mod…”
BackgroundMcGregor, C., Srisurapanont, M., Mitchell, A., Wickes, W., & White, J. M. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.12.003 · Cited by 82 · cited 1×
“mirtazapine for methamphetamine withdrawal supported the safety of modafinil 400 mg daily in an abstinent population; however, the safety of modafinil at 400 mg/d has not been established in patients who have the potential to use methamphetamine concurrently.(20) Thus, the goal of this open-label pilot study was to as…”
BackgroundMcElhiney, M. C., Rabkin, J. G., Rabkin, R., & Nunes, E. V. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802342907 · Cited by 61 · cited 1×
“For instance, a recent uncontrolled pilot study using modafinil (200 mg/d) plus cognitive behavioral therapy in HIV-positive men reported that 6 of 10 study completers reduced their methamphetamine use by more than 50%, although 2 of 13 participants enrolled discontinued their participation due to side effects.(18) Mo…”
Background
Cited by
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
A review of treatment options for co-occurring methamphetamine use disorders and depression
Hellem, T. L., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000058 · Cited by 51
Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study
Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Dual Diagnosis · doi:10.1080/15504263.2015.1100471 · Cited by 49
Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021791 · Cited by 42
“Recent randomized trials of modafinil to treat MA-dependent users (De La Garza et al., 2010; Heinzerling et al., 2010; McElhiney et al., 2009; McGaugh et al., 2009; McGregor et al., 2008; Shearer et al., 2009) have shown the drug to be well tolerated with limited side effects and minimal adverse events (particularly a…”
Background
Metadata
- Authors
- McGaugh, J., Mancino, M. J., Feldman, Z., Chopra, M. P., Gentry, W. B., Cargile, C., & Oliveto, A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2009-10
- Volume
- 29
- Issue
- 5
- Pages
- 488-491
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1969050883
- Cited by
- 31
- References
- 4
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.